A61K39/02

COMPOSITIONS AND METHODS FOR RAPID IN VITRO SYNTHESIS OF BIOCONJUGATE VACCINES IN VITRO VIA PRODUCTION AND N-GLYCOSYLATION OF PROTEIN CARRIERS IN DETOXIFIED PROKARYOTIC CELL LYSATES

Disclosed are methods, systems, components, and compositions for cell-free synthesis of glycosylated carrier proteins. The glycosylated carrier proteins may be utilized in vaccines, including anti-bacterial vaccines. The glycosylated carrier proteins may include a bacterial polysaccharide conjugated to a carrier, which may be utilized to generate an immune response in an immunized host against the polysaccharide conjugated to the carrier. The glycosylated carrier proteins may be synthesized in cell-free glycoprotein synthesis (CFGpS) systems using prokaryote cell lysates that are enriched in components for glycoprotein synthesis such as oligosaccharyltransferases (OSTs) and lipid-linked oligosaccharides (LLOs) including OSTs and LLOs associated with synthesis of bacterial O antigens.

PROTEINS AND NUCLEIC ACIDS FOR EHRLICHIA DIAGNOSIS AND VACCINATION

Methods and compositions for diagnosing and vaccinating against Ehrlichia canis and Ehrlichia chaffeensis are provided.

Nanoparticle vaccine adjuvant and methods of use thereof

Non-liposome, non-micelle particles formed of a lipid, an additional adjuvant such as a TLR4 agonist, a sterol, and a saponin are provided. The particles are porous, cage-like nanoparticles, also referred to as nanocages, and are typically between about 30 nm and about 60 nm. In some embodiments, the nanocages include or are administered in combination with an antigen. The particles can increase immune responses and are particularly useful as adjuvants in vaccine applications and related methods of treatment. Preferred lipids, additional adjuvants including TLR4 agonists, sterols, and saponins, methods of making the nanocages, and method of using them are also provided.

Nanoparticle vaccine adjuvant and methods of use thereof

Non-liposome, non-micelle particles formed of a lipid, an additional adjuvant such as a TLR4 agonist, a sterol, and a saponin are provided. The particles are porous, cage-like nanoparticles, also referred to as nanocages, and are typically between about 30 nm and about 60 nm. In some embodiments, the nanocages include or are administered in combination with an antigen. The particles can increase immune responses and are particularly useful as adjuvants in vaccine applications and related methods of treatment. Preferred lipids, additional adjuvants including TLR4 agonists, sterols, and saponins, methods of making the nanocages, and method of using them are also provided.

HAKIM POURCINA'S GAND ZODA-E
20230210972 · 2023-07-06 ·

A general serum procedure for all of pathogens with protein coding on an outer shell of the pathogens, comprises entering dead pathogens and their dead genomes to eliminate pathogens and cancer genes in humans and animals. A device for detecting pathogens in human body, animals, plants, water bodies, and air without blood test observes the spectral signature emitting from the human body and the water to match for any pathogens within the device’s database and uses electrostatic properties of the pathogens and their genomes to catch them.

HAKIM POURCINA'S GAND ZODA-E
20230210972 · 2023-07-06 ·

A general serum procedure for all of pathogens with protein coding on an outer shell of the pathogens, comprises entering dead pathogens and their dead genomes to eliminate pathogens and cancer genes in humans and animals. A device for detecting pathogens in human body, animals, plants, water bodies, and air without blood test observes the spectral signature emitting from the human body and the water to match for any pathogens within the device’s database and uses electrostatic properties of the pathogens and their genomes to catch them.

Fast diagnosis and personalized treatments for acne

Methods of diagnosing and treating patients afflicted with acne, including diagnosing one as having acne if the individual possesses RT4, RT5, RT7, RT8, RT9, or RT10. Methods for treating acne include administering an effective amount of a drug specifically targeting RT4, RT5, RT7, RT8, RT9, or RT10, such as small molecules, antisense molecules, siRNAs, biologics, antibodies, phages, vaccines, or combination thereof.

HU specific interfering agents

Methods of and compositions for breaking down a biofilm or inhibiting, preventing or treating a microbial infection that produces a biofilm are disclosed, which involves administration of an interfering agent capable of specifically competing, titrating, or inhibiting the binding of an HU protein to a microbial DNA. By competing with HU proteins that bind to DNA scaffold in the biofilm, these interfering agents destabilize the biofilm leading to destruction and removal of the biofilm by the immune system. Further method and composition aspects are contemplated in relation to infections caused by bacteria that export an HU protein.

<i>Coxiella burnetii </i>epitopes for T cell-targeted Q fever vaccines

Compositions and methods for inducing a protective immune response against Coxiella burnetii, to reduce a subject's risk of developing Q fever.

Flagellin-based agents and uses including effective vaccination

The present invention relates to, in part, compositions comprising improved flagellin derived constructs and methods of using for vaccination, including adjuvants comprising flagellin-based agents.